Theravance Biopharma Inc Cash Flow Conversion Efficiency

Latest as of September 2025: -0.028x

Theravance Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, Theravance Biopharma Inc (0TB) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.51 Million ≈ $-7.61 Million USD) by net assets (€232.68 Million ≈ $272.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Theravance Biopharma Inc (2014–2024)

Cash flow conversion efficiency of Theravance Biopharma Inc from 2014 to 2024. This chart illustrates how Theravance Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Theravance Biopharma Inc stock price for real-time trading data and today's change.

Theravance Biopharma Inc Cash Flow Conversion Ratio Explained

Theravance Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Theravance Biopharma Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Theravance Biopharma Inc ranked by their cash flow conversion efficiency. Also see 0TB stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Arctech Solar Holding Co Ltd SHG:688408	0.074x
Turk Traktor ve Ziraat Makineleri AS IS:TTRAK	0.079x
Huafu Top Dyed Melange Yarn Co Ltd SHE:002042	0.067x
Thungela Resources Limited JSE:TGA	0.156x
Heritage Commerce Corp NASDAQ:HTBK	0.028x
Zhejiang Xinhua Chemical Co Ltd SHG:603867	0.034x
Jinzhou Jixiang Molybdenum Co Ltd SHG:603399	-0.010x
Dongguan Kingsun Optoelectronic Co Ltd SHE:002638	-0.001x

Annual Cash Flow Conversion Efficiency for Theravance Biopharma Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of Theravance Biopharma Inc from 2014 to 2024. Review 0TB cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€175.54 Million ≈ $205.23 Million	€-11.54 Million ≈ $-13.49 Million	-0.066x	+48.16%
2023-12-31	€213.00 Million ≈ $249.01 Million	€-27.00 Million ≈ $-31.56 Million	-0.127x	+70.05%
2022-12-31	€441.80 Million ≈ $516.51 Million	€-186.99 Million ≈ $-218.61 Million	-0.423x	-168.94%
2021-12-31	€-338.57 Million ≈ $-395.83 Million	€-207.86 Million ≈ $-243.01 Million	0.614x	-25.53%
2020-12-31	€-303.75 Million ≈ $-355.12 Million	€-250.40 Million ≈ $-292.75 Million	0.824x	-22.53%
2019-12-31	€-223.84 Million ≈ $-261.69 Million	€-238.20 Million ≈ $-278.48 Million	1.064x	-51.36%
2018-12-31	€-51.59 Million ≈ $-60.31 Million	€-112.87 Million ≈ $-131.95 Million	2.188x	+225.33%
2017-12-31	€115.18 Million ≈ $134.66 Million	€-201.05 Million ≈ $-235.05 Million	-1.746x	-517.60%
2016-12-31	€350.23 Million ≈ $409.46 Million	€-98.99 Million ≈ $-115.73 Million	-0.283x	+59.31%
2015-12-31	€243.06 Million ≈ $284.17 Million	€-168.86 Million ≈ $-197.41 Million	-0.695x	-14.94%
2014-12-31	€289.79 Million ≈ $338.79 Million	€-175.16 Million ≈ $-204.77 Million	-0.604x	--

About Theravance Biopharma Inc

F:0TB Germany Biotechnology

Market Cap

$870.85 Million

€744.88 Million EUR

Market Cap Rank

#9466 Global

#1192 in Germany

Share Price

€14.70

Change (1 day)

+0.00%

52-Week Range

€11.60 - €17.50

All Time High

€38.30